CNS lymphoma · 5 regimens
Cost vs Efficacy
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
Cytarabine, Methotrexate, Rituximab Variant #01 | — | R 29 571 | 21d | — | — | — | — | — |
MATRix Variant #01 Partial | — | R 29 571 | 21d | — | — | — | — | — |
Cytarabine and Methotrexate (CYM) Variant #03 | — | R 5 979 | 21d | — | — | — | — | — |
MBVP Variant #01 Partial | — | R 227 | 28d | — | — | — | — | — |
Methotrexate monotherapy Partial | — | — | — | ~2.6 mo | ~6.7 mo | — | — | 10 |
5 of 5 regimens shown